Professor, Department of Pharmacology, V. P. Chest Institute, University of Delhi, Delhi, India.
Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, Missouri, USA.
Indian J Public Health. 2020 Jun;64(Supplement):S112-S116. doi: 10.4103/ijph.IJPH_456_20.
A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal.
一种由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年新型冠状病毒病（COVID-19）感染于 2019 年 12 月在中国武汉首次出现，现已成为全球大流行。目前，COVID-19 感染的管理主要是支持性的。全球有几项临床试验正在评估几种已批准用于其他适应症的药物，以及多种用于治疗和预防 COVID-19 的研究性药物。在这里，我们简要概述了正在作为治疗选择或辅助药物用于感染 COVID-19 的患者以及用于预防 COVID-19 感染的化学预防的药理学药物和其他疗法。在撰写本评论时，没有来自 COVID-19 患者的随机临床试验的任何药理学药物改善结果的同行评审发表证据。然而，据报道，瑞德西韦是一种研究性抗病毒药物，可以加速临床康复，但一项研究尚未在同行评审的医学期刊上发表。
